Accelerating and Improving Drug Discovery
Forum for patient advocates explores how researchers are working to develop cancer treatments in a quicker, more efficient manner.
Progress Against Cancer
Forum for patient advocates explores how researchers are working to develop cancer treatments in a quicker, more efficient manner.
Cancer drug shortages affect pediatric care, and ‘power dynamics’ limit women’s access to cancer care globally.
Approvals issued in July, August, and September 2023 included a new treatment for prostate cancer harboring BRCA mutations, two new bispecific T-cell engagers for multiple myeloma, a special kit to treat liver metastases from uveal melanoma, and more.
Based on estimates from the National Cancer Institute, in 2023, more than 110,000 cases of gynecologic cancers are expected to be diagnosed in the U.S., and approximately 34,000 people will die from these diseases. ...
A targeted therapy previously approved for adults is now available for certain pediatric patients with blood cancer. The U.S. Food and Drug Administration (FDA) has approved bosutinib (Bosulif) for pediatric patients who are at...
Study links proper dental hygiene to increased survival in head and neck cancer, and researchers use breast milk to detect breast cancer in new mothers.
In combination with stem cell transplant, vaccination-induced immune response and was associated with long-term control of the disease. Cancer scientists have developed a vaccine that may improve the response to therapy in patients with...
New report charts progress in cancer care, and immediate access to test results can lead to confusion.
The FDA Project Renewal initiative has updated the approved indications for temozolomide chemotherapy in anaplastic astrocytoma. The U.S. Food and Drug Administration (FDA) has approved updated labeling of temozolomide (Temodar), including new and revised...
Results of a recent study support concerns that pandemic disruptions resulted in finding fewer cancers.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More